Relief And Rebuke For Biocon In Herceptin Biosimilars Case

An Indian court did not hold back the launch of Biocon's biosimilar version of Roche's Herceptin (trastuzumab) for two additional indications - early breast cancer and metastatic gastric cancer - but had some tough words against the Bengaluru-based firm on its apparent "conduct" in obtaining regulatory approval of the carton, labels and the package insert.